About Eaton Scientific Systems, Ltd.

Eaton Scientific Systems, Ltd. ("Eaton") was founded in January 2006 in Los Angeles, CA and headquartered in Beverly Hills California with the mandate to develop, license and seek U.S. and International regulatory approvals of its drugs and treatments targeting womens health.

Eaton’s acquisition of a novel indication of Homatropine, is currently patent pending with the United States Patent and Trademark Office. Our novel indication is for an oral suspension of Homatropine prescribed to target climeratic conditions known as "Hot Flashes".

The Company has named the new indication of Homatropine "Tropine 3". Tropine 3 is an orally ingested prescription product containing Homatropine that is intended to reduce climacteric symptoms and improve quality of life in menopausal women not receiving HRT (women who are experiencing "hot flashes" and "night sweats"). To date, doctors in Los Angeles, CA have prescribed a compound version of Tropine 3 to their patients who are experiencing hot flashes.  

Homatropine, an ingredient in a Food and Drug Administration ("F.D.A.") approved prescription anti-tussive (capable of relieving or suppressing coughing), was isolated by Rox-San Pharmacy, located in Beverly Hills, California.

The Company has retained a team of accredited medical professionals and is presently drafting the final elements of its Protocol in order to obtain FDA approval to commence a Clinical Trial (the "Trial"). The purpose of the clinical trial will be to obtain the regulatory approval of Tropine 3 by the Food & Drug Administration ("F.D.A."). 

The Trial will look at the specificity and efficacy of the drug Homatropine in an oral suspension to see if it will provide relief of hot flashes and night sweats and improve the quality of life in women dealing with hot flashes or experiencing menopausal symptoms. 

Homatropine has almost 40 years of visibility and is already a generic drug; therefore the trial will not be looking at toxicity which is almost always a main reason for a drugs delay in obtaining a regulatory approval. The Company anticipates that the Study will be completed, barring any unforeseen delays, some time during the 2nd calendar quarter of 2013.

The Clinical Trial will be a Phase 2-3, Prospective, Randomized, Double Blind, Placebo-Controlled, Dose Escalation, Parallel-Group-Study to Test the Efficacy and Safety of Homatropine Methylbromide Oral Suspension on Selected Climacteric Symptoms and Quality of Life in Menopausal Women Not Receiving HRT.